Athens 2016:Cornea Day (Section 1)

Question Title

* 1. Name and/or Badge ID Number:

Question Title

* 2. Professional Situation:

Resident

Hospital Staff

Private Practice

Industry

Ophthalmic Assistant

University

Question Title

* 3. Areas of interest:

Cataract

Refractive Surgery

Cornea

Glaucoma

Retina

Other (please specify)

Question Title

* 4. How did you rate the course content?

Excellent

Good

Satisfactory

Poor

Question Title

* 5. SECTION 1: Ocular Surface Disease: What Worked and What Did Not
How would you rate the presentation of each presenter?

	Excellent	Good	Average	Poor
M. Labetoulle: Efficacy and pitfalls of diagnostic methods of viral diseases of the ocular surface	M. Labetoulle: Efficacy and pitfalls of diagnostic methods of viral diseases of the ocular surface Excellent	M. Labetoulle: Efficacy and pitfalls of diagnostic methods of viral diseases of the ocular surface Good	M. Labetoulle: Efficacy and pitfalls of diagnostic methods of viral diseases of the ocular surface Average	M. Labetoulle: Efficacy and pitfalls of diagnostic methods of viral diseases of the ocular surface Poor
A. McElvanney: Sudden onset of uniocular cicatrisation associated with a skin rash	A. McElvanney: Sudden onset of uniocular cicatrisation associated with a skin rash Excellent	A. McElvanney: Sudden onset of uniocular cicatrisation associated with a skin rash Good	A. McElvanney: Sudden onset of uniocular cicatrisation associated with a skin rash Average	A. McElvanney: Sudden onset of uniocular cicatrisation associated with a skin rash Poor
E. Mrukwa-Kominek: New generation eye drops with cyclosporin A in the treatment of severe dry eye syndrome: case report	E. Mrukwa-Kominek: New generation eye drops with cyclosporin A in the treatment of severe dry eye syndrome: case report Excellent	E. Mrukwa-Kominek: New generation eye drops with cyclosporin A in the treatment of severe dry eye syndrome: case report Good	E. Mrukwa-Kominek: New generation eye drops with cyclosporin A in the treatment of severe dry eye syndrome: case report Average	E. Mrukwa-Kominek: New generation eye drops with cyclosporin A in the treatment of severe dry eye syndrome: case report Poor
P. Antonopoulou: Dramatic resolution of acne rosacea and secondary ocular surface disease after a 14 day course of azithromycin 1.5% eye drops	P. Antonopoulou: Dramatic resolution of acne rosacea and secondary ocular surface disease after a 14 day course of azithromycin 1.5% eye drops Excellent	P. Antonopoulou: Dramatic resolution of acne rosacea and secondary ocular surface disease after a 14 day course of azithromycin 1.5% eye drops Good	P. Antonopoulou: Dramatic resolution of acne rosacea and secondary ocular surface disease after a 14 day course of azithromycin 1.5% eye drops Average	P. Antonopoulou: Dramatic resolution of acne rosacea and secondary ocular surface disease after a 14 day course of azithromycin 1.5% eye drops Poor
D. Pavlenko: Patient compliance as an effectiveness factor of complicated dendritic herpetic keratitis treatment	D. Pavlenko: Patient compliance as an effectiveness factor of complicated dendritic herpetic keratitis treatment Excellent	D. Pavlenko: Patient compliance as an effectiveness factor of complicated dendritic herpetic keratitis treatment Good	D. Pavlenko: Patient compliance as an effectiveness factor of complicated dendritic herpetic keratitis treatment Average	D. Pavlenko: Patient compliance as an effectiveness factor of complicated dendritic herpetic keratitis treatment Poor
J. Ashar: Comparison of ROSE K XL, miniscleral (MS) and scleral (S) contact lens (CL) for ocular surface disorders	J. Ashar: Comparison of ROSE K XL, miniscleral (MS) and scleral (S) contact lens (CL) for ocular surface disorders Excellent	J. Ashar: Comparison of ROSE K XL, miniscleral (MS) and scleral (S) contact lens (CL) for ocular surface disorders Good	J. Ashar: Comparison of ROSE K XL, miniscleral (MS) and scleral (S) contact lens (CL) for ocular surface disorders Average	J. Ashar: Comparison of ROSE K XL, miniscleral (MS) and scleral (S) contact lens (CL) for ocular surface disorders Poor
C. Kalamkar: Profile, treatment and outcomes of ocular surface squamous neoplasia (OSSN) in a rural population of central India	C. Kalamkar: Profile, treatment and outcomes of ocular surface squamous neoplasia (OSSN) in a rural population of central India Excellent	C. Kalamkar: Profile, treatment and outcomes of ocular surface squamous neoplasia (OSSN) in a rural population of central India Good	C. Kalamkar: Profile, treatment and outcomes of ocular surface squamous neoplasia (OSSN) in a rural population of central India Average	C. Kalamkar: Profile, treatment and outcomes of ocular surface squamous neoplasia (OSSN) in a rural population of central India Poor
Q. Palomino: Clinical management of ulcer perforation due to facial paralysis	Q. Palomino: Clinical management of ulcer perforation due to facial paralysis Excellent	Q. Palomino: Clinical management of ulcer perforation due to facial paralysis Good	Q. Palomino: Clinical management of ulcer perforation due to facial paralysis Average	Q. Palomino: Clinical management of ulcer perforation due to facial paralysis Poor
V. Achtsidis : Ocular surface disease secondary to corneal hypoesthesia and denervation in subjects with diabetic neuropathy	V. Achtsidis : Ocular surface disease secondary to corneal hypoesthesia and denervation in subjects with diabetic neuropathy Excellent	V. Achtsidis : Ocular surface disease secondary to corneal hypoesthesia and denervation in subjects with diabetic neuropathy Good	V. Achtsidis : Ocular surface disease secondary to corneal hypoesthesia and denervation in subjects with diabetic neuropathy Average	V. Achtsidis : Ocular surface disease secondary to corneal hypoesthesia and denervation in subjects with diabetic neuropathy Poor
J. Asher: Paired eye comparison of cyclosporine (CSA) 0.05% and chloroquine (CHQ) eye drops for moderate dry eyes	J. Asher: Paired eye comparison of cyclosporine (CSA) 0.05% and chloroquine (CHQ) eye drops for moderate dry eyes Excellent	J. Asher: Paired eye comparison of cyclosporine (CSA) 0.05% and chloroquine (CHQ) eye drops for moderate dry eyes Good	J. Asher: Paired eye comparison of cyclosporine (CSA) 0.05% and chloroquine (CHQ) eye drops for moderate dry eyes Average	J. Asher: Paired eye comparison of cyclosporine (CSA) 0.05% and chloroquine (CHQ) eye drops for moderate dry eyes Poor
A.J Kanellopoulos: Refractive power changes in ectasia management with the Athens Protocol (AP): topo-guided PTK and CXL	A.J Kanellopoulos: Refractive power changes in ectasia management with the Athens Protocol (AP): topo-guided PTK and CXL Excellent	A.J Kanellopoulos: Refractive power changes in ectasia management with the Athens Protocol (AP): topo-guided PTK and CXL Good	A.J Kanellopoulos: Refractive power changes in ectasia management with the Athens Protocol (AP): topo-guided PTK and CXL Average	A.J Kanellopoulos: Refractive power changes in ectasia management with the Athens Protocol (AP): topo-guided PTK and CXL Poor

Question Title

* 6. Comments: